Xenetic Biosciences (XBIO) investor relations material

Executive summary

• Q3 2026 net loss widened to $1.70M from $0.51M YoY, as lower Takeda royalties and higher acquisition-related G&A outweighed reduced R&D spending.

• The proposed Santersus acquisition would combine two NET-targeting approaches; Santersus holders are expected to own ~85% of the combined company at closing, subject to adjustments and approvals.

Financial highlights

• Q3 royalty revenue fell 29.4% YoY to $725K; 9M revenue declined 0.8% to $2.19M, primarily reflecting prior-year positive royalty adjustments from certain countries.

• Q3 operating expenses rose 56.8% YoY to $2.46M; 9M expenses increased 22.3% to $5.41M, with higher acquisition-related G&A partly offset by lower R&D.

• Q3 net loss was $1.70M vs. $510K; 9M net loss was $3.08M vs. $2.10M. Q3 basic and diluted loss per share was $0.72 vs. $0.33; 9M was $1.33 vs. $1.36.

• Cash was $5.81M at September 30, 2026, vs. $7.88M at December 31, 2025; current liabilities were $1.90M vs. $968K.

Outlook and guidance

• Management expects operating losses to continue near term, believes existing resources can fund operations for at least 12 months from issuance, and anticipates needing additional capital longer term.

• Development focus remains advancing systemic DNase toward clinical development as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

• The Santersus transaction remains conditional on stockholder, registration, Nasdaq listing and other customary approvals; closing timing and final ownership remain uncertain.